問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Others--

Division of General Internal Medicine

Division of General Internal Medicine

Taichung Veterans General Hospital

Division of Cardiovascular Diseases

National Taiwan University Hospital Hsin-Chu Branch

Division of Hematology & Oncology

CHANGHUA CHRISTIAN HOSPITAL

Division of Hematology & Oncology

更新時間：2023-09-19

吳尚儒Wu, Shang-Ju
  • Principal Investigator
  • Clinical Trial Experience (year) 18 years 1 個月

Recruiting Trial

74Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳尚儒

List

134Cases

2011-07-19 - 2013-10-17

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2012-02-09 - 2014-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2009-03-01 - 2017-03-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2019-04-01 - 2020-01-02

Others

A Phase Ib, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas

  • Condition/Disease

    Advanced/Metastatic Solid Tumors or Lymphomas

  • Test Drug

    MIW815 (ADU-S100) , PRD001

Participate Sites
1Sites

Terminated1Sites

2022-12-05 - 2024-09-30

Phase III

A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA

  • Condition/Disease

    Prevention of Ischemic Stroke 、Acute Non-cardioembolic Ischemic Stroke、 High-risk Transient Ischemic Attack

  • Test Drug

    AsundexianPlacebo (for Asundexian)ApixabanPlacebo (for Apixaban)

Participate Sites
23Sites

Not yet recruiting2Sites

Recruiting20Sites

Terminated1Sites

2017-07-20 - 2025-05-20

Phase III

A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

  • Condition/Disease

    Lymphoma, Non-Hodgkin

  • Test Drug

    BAY 80-6946 (copanlisib)；phosphatidylinositol 3-kinase (PI3K) inhibitor

Participate Sites
5Sites

Recruiting1Sites

Terminated4Sites

2017-05-16 - 2022-07-26

Phase III

A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3

  • Condition/Disease

    Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

  • Test Drug

    BAY 80-6946 (copanlisib)；phosphatidylinositol 3-kinase (PI3K) inhibitor

Participate Sites
5Sites

Terminated5Sites

2015-05-01 - 2018-12-19

Phase III

A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin’s lymphoma (iNHL) – CHRONOS-2

  • Condition/Disease

    indolent non-Hodgkin’s lymphoma (iNHL)

  • Test Drug

    BAY 80-6946

Participate Sites
2Sites

Terminated2Sites

2013-01-15 - 2018-01-30

Phase III

A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

  • Condition/Disease

    Chronic Myeloid Leukemia

  • Test Drug

    AP24534

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

2016-07-01 - 2018-05-03

Phase I

An open label, phase I trial of intravenous administration of volasertib as monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome after hypomethylating agents treatment failure

  • Condition/Disease

    myelodysplastic syndrome, MDS

  • Test Drug

    Volasertib

Participate Sites
3Sites

Terminated2Sites

1 10 11 12 13 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB